Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Cash from Financing Activities
Zealand Pharma A/S
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash from Financing Activities
kr8.3B
|
CAGR 3-Years
84%
|
CAGR 5-Years
65%
|
CAGR 10-Years
41%
|
|
|
Genmab A/S
CSE:GMAB
|
Cash from Financing Activities
-kr3.9B
|
CAGR 3-Years
-111%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash from Financing Activities
€443.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
25%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash from Financing Activities
kr55.8m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-13%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash from Financing Activities
kr75.5m
|
CAGR 3-Years
309%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Cash from Financing Activities
kr23.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
3%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Cash from Financing Activities?
Cash from Financing Activities
8.3B
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Cash from Financing Activities amounts to 8.3B DKK.
What is Zealand Pharma A/S's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
41%
Over the last year, the Cash from Financing Activities growth was 814%. The average annual Cash from Financing Activities growth rates for Zealand Pharma A/S have been 84% over the past three years , 65% over the past five years , and 41% over the past ten years .
You don't have any saved screeners yet